This Article Full Text Full Text (PDF) All Versions of this Article: 36/6/1291    most recent 01.STR.0000166055.52742.2bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brown, D. L. Articles by Morgenstern, L. B. Search for Related Content PubMed PubMed Citation Articles by Brown, D. L. Articles by Morgenstern, L. B. Related Collections Health policy and outcome research Other Stroke Treatment - Medical Related Article

(Stroke. 2005;36:1291.)
© 2005 American Heart Association, Inc.

Research Reports

Screening for Obstructive Sleep Apnea in Stroke Patients

A Cost-Effectiveness Analysis

Devin L. Brown, MD; Ronald D. Chervin, MD, MS; Susan L. Hickenbottom, MD, MS; Kenneth M. Langa, MD, PhD Lewis B. Morgenstern, MD

From the Stroke Program (D.L.B., S.L.H., L.B.M.), Sleep Disorders Center (R.D.C.), and Division of General Medicine (K.M.L.), University of Michigan Health System, Ann Arbor.

Correspondence to Devin L. Brown, MD, TC 1920/0316, 1500 E Medical Center Dr, University of Michigan, Ann Arbor, MI 48109. E-mail devinb{at}med.umich.edu

Background and Purpose— Obstructive sleep apnea (OSA) is common after acute ischemic stroke and predicts poor stroke recovery, but whether screening for OSA and treatment by continuous positive airway pressure (CPAP) improves neurological outcome is unknown. We used a cost-effectiveness model to estimate the magnitude of benefit that would be necessary to make polysomnography (PSG) and OSA treatment cost-effective in stroke patients.

Methods— A decision tree modeled 2 alternative strategies: PSG followed by 3 months of CPAP for those found to have OSA versus no screening. The primary outcome was the utility gained through OSA screening and treatment in relation to 2 common willingness-to-pay thresholds of $50 000 and $100 000 per quality-adjusted life year (QALY).

Results— Screening resulted in an incremental cost-effectiveness ratio of $49 421 per QALY. Screening is cost-effective as long as the treatment of stroke patients with OSA by CPAP improves patient utilities by >0.2 for a willingness-to-pay of $50 000 per QALY and 0.1 for a willingness-to-pay of $100 000 per QALY.

Conclusions— A clinical trial assessing the effectiveness of CPAP in improving stroke outcome is warranted from a cost-effectiveness standpoint.

Key Words: cost–benefit analysis • sleep apnea, obstructive • stroke management

Related Article:

How Much Is a Good Night’s Sleep Worth?

Linda S. Williams and Robert G. Holloway
Stroke 2005 0: 01.STR.0000168860.45858.10v1. [Abstract] [PDF]

This article has been cited by other articles:

				W. T. McNicholas, M. R. Bonsignore, and the Management Committee of EU COST ACTION B26 Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities Eur. Respir. J., January 1, 2007; 29(1): 156 - 178. [Abstract] [Full Text] [PDF]

				L. S. Williams and R. G. Holloway Editorial Comment: How Much Is a Good Night's Sleep Worth? Stroke, June 1, 2005; 36(6): 1293 - 1294. [Full Text] [PDF]